Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.67 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | AXL | P30530 | 1/20 | 0.62 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.62 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28784680 | 0.88 | HDAC6 (0.74) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL31351012 | 0.86 | HDAC6 (0.72) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL369871 | 0.86 | HDAC6 (0.72) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL1812154 | 0.85 | HDAC6 (0.70) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL13602299 | 0.85 | HDAC6 (0.70) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL31350948 | 0.85 | HDAC6 (0.70) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL5009761 | 0.84 | HDAC6 (0.68) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL24755152 | 0.82 | HDAC6 (1.00) | HDAC6IRAK4TLR7RAB9ANPC1 | |
| SCHEMBL4735788 | 0.82 | HPGD (0.64) | HDAC6TLR7RAB9ANPC1MAPK1 | |
| SCHEMBL168291 | 0.82 | TDP1 (0.67) | HDAC6IRAK4TLR7RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016166250-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | QURIENT CO., LTD (KR) | 2016-10-20 | — | — | WO | disclosed |
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| CN-1146542-C | Benzamide derivatives and their use as cytokine inhibitors | — | 2004-04-21 | — | — | CN | disclosed |
| EP-0811008-B1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0811008-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5696112-A | TREATMENT OF CONGESTIVE HEART FAILURE, CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-09 | — | — | US | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HDAC6 2209/4885IRAK4 1458/4885TLR7 428/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | HDAC6 2209/4885IRAK4 1458/4885TLR7 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.